irinotecan (Camptosar)

Subscribe to Selected New Research on irinotecan

2916 relevant articles (497 outcomes, 1113 trials/studies) found for this Drug

Description: RN given for mono-HCL(S)-isomer; structure given in first source

Also Known As:

Camptosar; CPT 11; SN 38; 7-ethyl-10-hydroxycamptothecin; CPT-11; Irrinotecan; SN 38 11; SN-38; SN-38-11; camptothecin-11; irinotecan hydrochloride

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 23

Alkaloids: 633

Camptothecin: 1048

irinotecan: 2916

Experts

1.	Georgoulias, V: 20 articles (01/2008 - 06/2000)
2.	Souglakos, J: 14 articles (01/2008 - 06/2000)
3.	Goldberg, Richard M: 13 articles (09/2007 - 01/2002)
4.	Fuchs, Charles S: 12 articles (02/2008 - 03/2003)
5.	Kakolyris, S: 12 articles (01/2008 - 06/2000)
6.	Androulakis, N: 12 articles (01/2008 - 01/2001)
7.	Kiura, Katsuyuki: 12 articles (06/2007 - 01/2002)
8.	Fukuoka, M: 12 articles (02/2007 - 03/2000)
9.	Lee, Jin Soo: 11 articles (09/2008 - 12/2003)
10.	Han, Ji-Youn: 11 articles (09/2008 - 12/2003)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 11/01/2001 - "CONCLUSIONS: Weekly CPT-11/5-FU/FA is highly effective in the treatment of patients with metastatic colorectal cancer limited to the liver, even after failure of previous 5-FU/FA" 08/01/2000 - "Thus, considering other encouraging data from the literature, the CPT-11 + FU-LV combination therapy can be regarded as a new, very effective treatment option for first-line treatment of advanced colorectal cancer patients." 01/01/2008 - "This study aimed to determine the safety and efficacy of high-dose (HD) irinotecan combined with LV5FU2 or simplified LV5FU (LV5FUs) in first-line treatment of metastatic colorectal cancer" 03/01/2008 - "No significant relationship was found between CES2 830C>G genotype and the toxicity and therapeutic efficacy (tumour response, event-free survival) of irinotecan in colorectal cancer patients" 07/01/2007 - "The response rate of the patients receiving CPT-11 at a dose of 150 mg/m2 was comparable to that reported previously for 5-FU-based regimens coupled with CPT-11, and this regimen can probably be beneficial for patients with pre-treated advanced colorectal cancer on an outpatient basis." Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 08/16/2004 - "The role of the UGT1A1 genotype as a predictor of toxicity in cancer patients receiving irinotecan demands the performance of a randomized trial to ascertain whether genotype-adjusted dosages of the drug can help to establish safe and effective doses not only for patients with the UGT1A1()28 homozygous genotype but also for those with the most common UGT1A1 6/6 or 6/7 genotype." 03/01/2007 - "The chemotherapeutic agent irinotecan (IT) is highly effective against several types of cancer, although its use is limited due to severe intestinal toxicity" 04/01/2004 - "RESULTS: HACE with irinotecan induced a complete remission in 44% of the animals and the highest dose reduced the mean tumor cell load by 66% (P < 0.001)" 03/01/2007 - "ND-GFP nude mice that were administered CPT-11 showed significant reduction in the mean nascent blood vessel density and tumor volume" 10/15/2004 - "However, combined with irinotecan (CPT-11), significantly greater than additive activity was observed in four of eight models (P < 0.05), and the combination showed enhanced activity against three additional tumor lines" Get all the results and reference details, order at left...*
3.	Small Cell Carcinoma (Small Cell Lung Cancer) 05/01/1991 - "The results showed that CPT-11 was highly effective against non-small cell and small cell carcinomas of the lung." 03/01/1998 - "PURPOSE: Irinotecan (CPT-11) is effective against small-cell lung cancer (SCLC) as monotherapy" 08/15/2008 - "Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505." 07/15/2004 - "The CPT-11 trial was conducted to confirm the superiority of CDDP+CPT-11 (CPT-P) arm to CDDP+VDS (VDS-P) arm with regard to survival for patients with previously untreated advanced (stage IIIB/IV) non-small-cell lung cancer" 07/01/2003 - "Similar North American phase III trials focusing on irinotecan's role in non-small-cell lung cancer are planned" Get all the results and reference details, order at left...
4.	Neoplasm Metastasis (Metastasis) 11/01/2007 - "HAI (WHF: 1000 mg/m2) plus CPT-11 (100 mg/m2) was effective, and liver metastases showed a significant reduction (PR) on abdominal CT" 03/01/2003 - "Combination therapy of FR-WBH + CPT-11 resulted in a significantly greater inhibition of axillary lymph node metastasis volume compared to both control and CPT-11 alone (p < 0.02) at day 16" 11/01/2007 - "HAI plus CPT-11 was effective for a patient of the poor performance status with unresectable liver metastasis." 02/01/2005 - "We analyzed the efficacy of isolated hepatic perfusion (IHP) for patients with progressive CRC liver metastases after irinotecan" 03/01/2003 - "Both the group treated with FR-WBH alone and the combined FR-WBH + CPT-11 group had delayed onset and reduced incidence of axillary lymph node metastases compared to control (p < 0.05)" Get all the results and reference details, order at left...
5.	Stomach Neoplasms (Stomach Cancer) 06/01/2007 - "CPT-11 appeared to be highly efficacious when given in combination with CDDP in human gastric cancer cell lines" 12/01/2007 - "The combination of 5-FU/LV and irinotecan as first-line treatment was found to be well tolerated and effective in patients with advanced gastric cancer" 09/01/2005 - "CONCLUSIONS: S-1 with CPT-11 can be combined safely without CPT-11 effect on S-1 PK data and holds promise as an effective regimen for advanced gastric cancer." 06/01/2007 - "Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer." 01/01/2007 - "BACKGROUND/AIMS: To investigate the efficacy and safety of the combination therapy of irinotecan (CPT-11) plus S-1 in patients with advanced gastric cancer at the dose recommended by a previous phase I study" Get all the results and reference details, order at left...
235 Diseases and 2916 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Fluorouracil (Carac)
2.	Leucovorin (Folinic Acid)
3.	oxaliplatin (Eloxatin)
4.	irinotecan (Camptosar)
5.	Cisplatin (Platino)
6.	capecitabine (Xeloda)
7.	Type I DNA Topoisomerases (Topoisomerase I)
8.	bevacizumab
9.	Paclitaxel (Taxol)
10.	docetaxel (Taxotere)
658 Drugs and Important Bio-Agents and 2420 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Salvage Therapy
5.	Neoadjuvant Therapy
36 Therapies and Procedures and 891 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>